Curasight (CURAS) Investor update summary

Capital raise and funding structure

• Launching a rights issue to raise up to DKK 100 million, extending cash runway to H2 2026 and supporting parallel development of diagnostic and therapeutic platforms.

• Subscription period runs from 2 May to 16 May 2025, with a price of DKK 1.98 per share.

• Subscription and guarantee commitments cover approximately 47% of the issue, including significant commitments from Curium, Pentwater, management, and other guarantors.

Use of proceeds and clinical milestones

• Proceeds will fund completion of Phase I trial for uTREAT® in brain cancer and Phase II trial for uTRACE® in prostate cancer, with key data readouts expected in H2 2025 and H1 2026.

• Additional funds allocated for working capital and first patient inclusion in uTREAT® Phase II for brain cancer in H1 2026.

Product pipeline and market potential

• uTRACE® and uTREAT® platforms target multiple cancers, with clinical trials planned or underway in glioblastoma, prostate, lung, head & neck, and neuroendocrine tumors.

• Market potential estimated at EUR 195 million annually for uTRACE® imaging and EUR 5.1 billion for uTREAT® therapy in brain cancer; EUR 1 billion annually for uTRACE® in prostate cancer.